209394-46-7

Basic information

• Product Name: Ladostigil tartrate
• Synonyms: ethylmethyl-carbamic acid (3r)-2,3-dihydro-3-(2-propynylamino)-1h-inden-5-yl ester (2r,3r)-2,3-dihydroxybutanedioate (2:1);ladostigil tartrate;Tv 3326;Unii-2J1346C51h;N-Ethyl-N-MethylcarbaMic Acid (3R)-2,3-Dihydro-3-(2-propyn-1-ylaMino)-1H-inden- 5-yl Ester (2R,3R)-2,3-Dihydroxybutanedioate;Burixafor
• CAS NO: 209394-46-7
• Molecular Formula: 0C₄H₆O₆*C₁₆H₂₀N₂O₂
• Molecular Weight: 694.777
• Product Categories: Amines;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 209394-46-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 412.4 °C at 760 mmHg
• Flash Point: 203.2 °C
• Appearance: /
• Vapor Pressure: 5.19E-07mmHg at 25°C
• CAS DataBase Reference: Ladostigil tartrate(CAS DataBase Reference)
• NIST Chemistry Reference: Ladostigil tartrate(209394-46-7)
• EPA Substance Registry System: Ladostigil tartrate(209394-46-7)

Safety Data

• Hazardous Substances Data: 209394-46-7(Hazardous Substances Data)

Usage

Description

Ladostigil tartrate is a novel brain-selective monoamine oxidase (MAO) inhibitor with potential applications in the treatment of various neurodegenerative and psychiatric disorders. It possesses the ability to selectively reverse the behavioral and neurochemical effects induced by prenatal stress, making it a promising candidate for the development of new therapeutic strategies.

Uses

Used in Pharmaceutical Industry:
Ladostigil tartrate is used as an antidepressant for the treatment of depression. It selectively reverses the behavioral and neurochemical effects induced by prenatal stress without affecting the behavior of controls, offering a potential therapeutic option for patients suffering from depressive disorders.
Used in Neurodegenerative Disease Treatment:
Ladostigil tartrate is used as a neuroprotective agent for the treatment of neurodegenerative diseases. Its ability to modulate monoamine oxidase activity and provide neuroprotection makes it a promising candidate for the development of new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and other related disorders.

InChI:InChI=1/2C16H20N2O2.C4H6O6/c2*1-4-10-17-15-9-7-12-6-8-13(11-14(12)15)20-16(19)18(3)5-2;5-1(3(7)8)2(6)4(9)10/h2*1,6,8,11,15,17H,5,7,9-10H2,2-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t2*15-;1-,2-/m111/s1

Upstream product

• 87-69-4 L-Tartaric acid 
• 209394-27-4 ladostigil 

Relevant articles and documents

Methods for isolating propargylated aminoindans

Disclosed is a process for isolating from a reaction mixture a salt of a mono-propargylated aminoindan having the structure wherein R1 is H, hydroxyl, alkoxy or wherein Y is O or S; R2 and R3 is each, independently, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl, each optionally halo substituted, or hydrogen; where the reaction mixture further comprises a solvent, a primary aminoindan having the structure wherein R1 is defined as above, and a tertiary aminoindan having the structure the process comprising d) adding an acid to the reaction mixture; e) crystallizing the mono-propargylated aminoindan under conditions suitable for the formation of a crystalline salt of the mono-propargylated aminoindan; and f) recovering the crystalline salt of the mono-propargylated aminoindan, wherein the process is performed without addition of an organic solvent. Also disclosed are the crystalline diastereomeric salts produced by the process and pharmaceutical compositions containing the salts.

METHODS FOR PREPARATION OF LADOSTIGIL TARTRATE CRYSTALLINE FORM A1

Provided are processes for preparing crystalline ladostigil tartrate form A1.

Formulations of ladostigil tartrate

Disclosed are formulations of ladostigil tartrate, including pharmaceutical compositions, process for the manufacture, and use thereof.